Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
3.300
+0.040 (1.23%)
At close: Jan 17, 2025, 4:00 PM
3.180
-0.120 (-3.64%)
After-hours: Jan 17, 2025, 7:55 PM EST
Citius Pharmaceuticals Stock Forecast
CTXR's stock price has decreased by -82.4% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CTXR stock have an average target of 54.5, with a low estimate of 9.00 and a high estimate of 100. The average target predicts an increase of 1,551.52% from the current stock price of 3.30.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTXR stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +172.73% | Jan 7, 2025 |
| D. Boral Capital | D. Boral Capital | Hold → Strong Buy Upgrades $9 | Hold → Strong Buy | Upgrades | $9 | +172.73% | Dec 30, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +2,930.30% | Nov 12, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $150 | Strong Buy | Maintains | $150 | +4,445.45% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
40.38M
Revenue Next Year
127.71M
from 40.38M
Increased by 216.25%
EPS This Year
-0.70
from -5.97
EPS Next Year
6.57
from -0.70
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 96.7M | 263.1M | 301.9M | ||
| Avg | 40.4M | 127.7M | 235.9M | ||
| Low | n/a | 56.2M | 171.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 551.4% | 136.4% | ||
| Avg | - | 216.3% | 84.7% | ||
| Low | - | 39.1% | 34.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.99 | 19.95 | 25.20 | ||
| Avg | -0.70 | 6.57 | 24.48 | ||
| Low | -4.41 | -0.91 | 23.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 283.6% | ||
| Avg | - | - | 272.7% | ||
| Low | - | - | 258.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.